In October 24th, the world pharmaceuticalraw materials exhibition (CPhI Worldwide) was held in Frankfurt, Germany, in2017. NKY medical group (NKY, stock code: 300109) subsidiary Boai NKYPharmaceuticals Limited attend this global pharmaceutical industry event with anew attitude - the large special booth, 11 line up of international marketingteam (including 5 employees from differentcountries overseas ) to participate in this event. Introduce the advanced andperfect products to the customers of the world with the new market strategy. NKY Pharmaceuticals has always attachedgreat importance to product development, continuously optimize the managementlevel and product quality, and strive to improve the level of cleanerproduction and sustainable development, to become international renowned producerand solution provider of medicinal materials and functional polymer. In this exhibition, vice chairman WangJianqiang of NKY medical group leading international sales team discussed anddetailed analysis of market strategy, develop a new strategy for theinternational market, and long-term sustainable development planning route ofNKY pharmaceuticals LTD. NKY PVP products and the OraRez products has attractedwide attention in the exhibition, we also promoted the new pharmaceuticalexcipients products of our partners.This exhibition, the German subsidiary of NKYgroup added a new marketing power and will play a key role in the progress ofEuropean business in the future .

Invited by the NKY medical group, the chief executive of Swedish NeoDynamics , Anna Eriksrud visit Beijing on 18~21th September. NeoDynamics is a medical technology company headquartered in Sweden, which is committed to research and develop tumor diagnosis equipment. NeoDynamics has now developed NeoNavia breast biopsy system, and in June 2016 acquired the European Union CE certification. From July 2016, NKY become the biggest shareholder in the NeoDynamics.This is the first time two sides communication in China after NKY become NeoDynamics shareholder, accompanied by Ms. Eriksrud to China, and on behalf of the NKY is professor?xiao-jun Xu, Xu teaches physiology and pharmacology in Karolinska instituteMs. Eriksrud first introduced the clinical results in Europe of NeoNavia in nearly a year to NKY: Till to September 2017, NeoNavia system has eight hospitals in clinical trials in Europe, biopsy sampling for breast cancer patients, accumulative total of around 100 cases, the success rate of about 95%. In addition, a small number of axillary lymph node biopsy is performed, with a success rate of up to 100%. The European doctors involved in clinical trials have given the NeoNavia system a high rating.Just in three days, Ms. Eriksrud respectively visited Beijing mammary gland disease prevention and control of society, the Chinese people's liberation army 307 hospital and scientific Chinese medicine tumor hospital. And has carried on the exchange communication respectively with Huang Yan team of 307 hospital surgical oncology and director wang team of mammary gland tumor hospital.Two experts understand the working principle of NeoNavia system in detail, compare the difference with the existing biopsy device and published their opinion, the two experts have expressed interest in cooperation for clinical testing in China.At the end of the trip, Ms. Eriksrud has strong confidence in the development prospects of NeoNavia in Chinese market. She believes that the rapid development of China's economy and the importance of early diagnosis and treatment of cancer will have a very positive impact on the market of medical products. NKY has excellent brand influence and market appeal in China, which can help to achieve the NeoDynamics market goal in China, and make a number of high technology of NeoDynamics benefit cancer patients.

Tianjin Boai NKY International Ltd., will be moving to a new office building next week, i.e. from 17th April 2017 we will be in the new office:

Tianjin, PR CHINA (September 15,2016) - BOAI NKY, the first Polyvinylpyrollidone (PVP) manufacturer in China and a significant manufacturer of methyl vinyl ether/maleic anhydride copolymers (PVM/MA), announces a major expansion to its Technical Support Labs. These enhanced facilities will provide our customers with outstanding support in helping them optimize their formulations in the Personal Care, Pharmaceutical and Performance Chemical markets for our range of PVP and PVM/MA polymer families.In addition, these enhanced Technical Support Labs will support BOAI NKY’s goal to broaden the application base of its OraRez® range of PVM/MA products. These products currently enjoy strengthening positions in the Oral Care market due to their excellent mucosal adhesive properties. To further build the OraRez® platform, BOAI NKY continues to develop new applications around their outstanding bioadhesive functionality, with special focus in the areas of skin protection and repair. Customers who are interested in making use of this expanded facility or discussing any of our products should contact Dr. Herb Ulmer as above or visit us at Stand 4H73, CPhI, Barcelona,October 4-6, 2016.ABOUT BOAI NKY. BOAI NKY Pharmaceuticals Ltd. (NKY stock code: 300109) was the first PVP manufacturer in China and has been manufacturing PVP’s for nearly 30 years. The Company opened a new “state of the art” manufacturing facility in Henan Province, PR China in 2013, making it the production center for our PVP and PVM/MA polymer families.All pharmaceutical, cosmetic, food and oral care polymers are manufactured under strict cGMP guidelines. With established R&D and Technical Centers, NKY is committed to the development of new products and technologies to bring new solutions and value to our customers.The Company operates through owned subsidiaries in Asia and Europe and with a network of specialist distributors. We serve customers in more than 60 countries worldwide.